Multivariate Screening and Automated Clustering of Macrophage Immunoreactome to Nanoparticles and Photothermal Therapy.

Fiche publication

Date publication

juin 2025

Journal

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROUX Stéphane

Tous les auteurs :
Becharef S, Jabbour L, Bekaddour N, Avveduto G, Luciani N, Laurent G, Bazzi R, Alphandery E, Roux S, Silva AKA, Aubertin K, Herbeuval JP, Gazeau F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40569571

Résumé

Immunotherapy aims to control the immune system against diseases such as cancer or infections. Nanotechnology is part of the armamentarium to reprogram the immune system in a spatially and temporally controlled manner. However, predicting immune responses using high-throughput tests is challenging due to the immunoreactome's complexity and plasticity. This work presents a fast, machine learning-assisted predictive assay to classify the multifactorial immune responses to any kind of treatments. Engineered human THP-1 monocytes differentiated and polarized into M0, M1, and M2 macrophages are used to monitor nuclear factor Kappa B (NF-kB) and interferon regulatory factor (IRF) pathway activations and gene expression profile in response to metallic nanoparticles (NPs), activated or not by light to induce photothermal therapy (PTT). Principal component analysis (PCA) reveals distinct responses to nanoparticles and the reprogramming toward inflammatory macrophage triggered by PTT. Gold-iron oxide nanoflowers and magnetosomes per se favor polarization toward M2 profile, while light activation shifts this M2-like macrophages toward an M1 phenotype. These findings, confirmed on human blood derived monocytes shed light on the intricate immunomodulatory effects of nanoparticles and PTT on macrophage behavior and provide a basis for an adaptable screening method for the predictive design of therapeutic strategies for immunotherapy in cancer and other diseases.